Harmony Biosciences Holdings Inc (OQ:HRMY)

Apr 16, 2024 08:05 am ET
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
PLYMOUTH MEETING, Pa., April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on April 30, 2024, at 8:30 a.m. ET to discuss the results.
Apr 11, 2024 08:05 am ET
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders. TPM-1116 represents a new chemical series of OX2R agonists with the potential for a best-in-class clinical profile.
Apr 03, 2024 08:05 am ET
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
PLYMOUTH MEETING, Pa., April 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate the safety and efficacy of pitolisant as a treatment for excessive daytime sleepiness (EDS) and behavioral symptoms in patients aged six years and older with Prader-Willi syndrome (PWS).
Mar 26, 2024 08:05 am ET
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa., March 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024, at 9:30 a.m. ET.
Feb 22, 2024 07:30 am ET
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today reported net revenue growth of more than 30% for the fourth quarter and full year ended December 31, 2023. “Harmony delivered another year of outstanding performance in 2023, with...
Feb 20, 2024 07:05 am ET
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME
PLYMOUTH MEETING, Pa., Feb. 20, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of Prader-Willi syndrome (PWS).
Feb 08, 2024 07:05 am ET
HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON FEBRUARY 22, 2024
PLYMOUTH MEETING, Pa., Feb. 8, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on February 22, 2024, at 8:30 a.m. ET to discuss the results.
Jan 08, 2024 07:05 am ET
HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE
WAKIX® (pitolisant) Preliminary Net Revenue of ~$168 Million for Fourth Quarter and ~$582 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively 
Jan 03, 2024 07:05 am ET
HARMONY BIOSCIENCES TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa., Jan. 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony, is scheduled to present at the conference on Wednesday, January 10, 2024, at 5:15 p.m. PT/8:15 p.m. ET.
Dec 07, 2023 07:05 am ET
HARMONY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT IN ADULT PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1
PLYMOUTH MEETING, Pa., Dec. 7, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY) today announced positive topline results from its Phase 2 signal detection study evaluating the safety and efficacy of pitolisant in adult patients with myotonic dystrophy type 1 (DM1).
Dec 05, 2023 07:05 am ET
HARMONY BIOSCIENCES TO PRESENT RESULTS FROM BEHAVIORAL STUDY IN 22Q11.2 DELETION SYNDROME AT AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING
PLYMOUTH MEETING, Pa., Dec. 5, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, will present caregiver-reported impacts of 22q11.2 deletion syndrome (22q) and data from the Phase 2 INSPIRE trial at the American College of Neuropsychopharmacology Annual Meeting from December 3-6, 2023.
Nov 16, 2023 07:05 am ET
HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 35th ANNUAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa., Nov. 16, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management team will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY on Thursday, November 30, 2023, at 9:00 a.m. ET.
Nov 15, 2023 07:05 am ET
HARMONY BIOSCIENCES RANKED AMONG TOP 25 FASTEST-GROWING COMPANIES IN NORTH AMERICA ON THE 2023 DELOITTE TECHNOLOGY FAST 500™
PLYMOUTH MEETING, Pa., Nov. 15, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, ranks 25th on the Deloitte Technology Fast 500™ for growing revenues 7,204% from fiscal year 2019 to 2022.
Nov 08, 2023 07:05 am ET
HARMONY BIOSCIENCES APPOINTS PETER ANASTASIOU TO ITS BOARD OF DIRECTORS
PLYMOUTH MEETING, Pa., Nov. 8, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Peter Anastasiou to the Company's Board of Directors.
Oct 31, 2023 07:30 am ET
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results...
Oct 26, 2023 08:05 am ET
HARMONY BIOSCIENCES SHOWCASES THE NEWEST PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD RECIPIENTS
PLYMOUTH MEETING, Pa., Oct. 26, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, has selected the latest round of nonprofit organizations for its Patients at the Heart and Progress at the Heart awards. These awards provide funding support to nonprofit organizations addressing the complex challenges affecting individuals with sleep disorders and rare neurological diseases through unique and impactful initiatives.
Oct 17, 2023 08:05 am ET
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS ON OCTOBER 31, 2023
PLYMOUTH MEETING, Pa., Oct. 17, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report third quarter 2023 financial results on Tuesday, October 31, 2023, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on October 31, 2023, at 8:30 a.m. ET to discuss the results.
Oct 13, 2023 08:00 am ET
HARMONY BIOSCIENCES ANNOUNCES TOPLINE DATA FROM PHASE 3 INTUNE STUDY EVALUATING PITOLISANT IN PATIENTS WITH IDIOPATHIC HYPERSOMNIA
PLYMOUTH MEETING, Pa., Oct. 13, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced topline results from the INTUNE study in patients with idiopathic hypersomnia (IH).
Oct 11, 2023 08:00 am ET
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
New product in development diversifies portfolio to drive long-term growth 
Oct 05, 2023 08:05 am ET
HARMONY BIOSCIENCES PRESENTS NEW SECONDARY OUTCOME DATA FROM PHASE 2 SIGNAL DETECTION STUDY IN PATIENTS WITH PRADER-WILLI SYNDROME
PLYMOUTH MEETING, Pa., Oct. 5, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the presentation of new secondary endpoint data, including improvements in behavioral disturbances, from its Phase 2 signal-detection study evaluating pitolisant for the treatment of excessive daytime sleepiness (EDS) in Prader-Willi syndrome (PWS), at the 2023 Foundation for Prader-Willi Research (FPWR) Symposiu
Sep 27, 2023 08:00 am ET
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
PLYMOUTH MEETING, Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), today announced that Xylophone Acquisition Corp., a wholly owned subsidiary of Harmony, has extended the expiration of its tender offer to acquire all of the outstanding shares of common stock of Zynerba Pharmaceuticals, Inc. ("Zynerba") (Nasdaq: ZYNE) to 5:00 p.m., New York City time, on Tuesday, October 10, 2023, unless further extended. The tender offer was previously scheduled to expire at 5:00 p.m., New York C
Sep 20, 2023 08:05 am ET
HARMONY BIOSCIENCES PRESIDENT & CEO JEFFREY M. DAYNO, M.D., NAMED TO 2023 PHARMAVOICE 100 LIST OF TOP INDUSTRY LEADERS
PLYMOUTH MEETING, Pa., Sept. 20, 2023 /PRNewswire/ -- Jeffrey M. Dayno, M.D., President & CEO of Harmony Biosciences, was named to the 2023 PharmaVoice 100 list for his unwavering commitment to bring clinical innovation and hope to patients living with rare neurological diseases. Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases.
Sep 13, 2023 08:05 am ET
HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa., Sept. 13, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management team will participate in a fireside chat at the upcoming 2023 Cantor Global Healthcare Conference in New York, NY on Wednesday, September 27, 2023, at 10:20 a.m. ET.
Aug 17, 2023 12:52 pm ET
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zynerba Pharmaceuticals, Inc. (NasdaqCM: ZYNE) to Harmony Biosciences Holdings, Inc. (NasdaqGM: HRMY). Under the terms of the proposed transaction, shareholders of Zynerba will receive only $1.1059 in cash for each share of Zynerba that they own, plus one non-tradeable contingent value right per share, representing the right to receive potential additional payments of up to $140 million in the aggregate, subject to the achievement of certain
Aug 14, 2023 03:58 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE), Chindata Group Holdings Limited (Nasdaq - CD), Capri Holdings Li
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Aug 01, 2023 07:30 am ET
Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results...
Aug 01, 2023 07:20 am ET
HARMONY BIOSCIENCES ANNOUNCES $125 MILLION SHARE REPURCHASE PROGRAM
PLYMOUTH MEETING, Pa., Aug. 1, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that its Board of Directors authorized the repurchase of up to $125 million of the Company's common stock.
Jul 27, 2023 08:05 am ET
HARMONY BIOSCIENCES ENTERS INTO $185 MILLION TERM LOAN FACILITY
PLYMOUTH MEETING, Pa., July 27, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced it has entered into a new $185 million senior secured term loan facility with a bank syndicate. Harmony intends to use the net proceeds from the term loan and existing cash to repay the Company's existing debt of $196.5 million and related fees and expenses. Additional information about the term loan is contained in the Company'
Jul 25, 2023 08:05 am ET
Harmony Biosciences Announces Funding for Unique Community Initiatives Through its Patients and Progress at the Heart Awards Programs
PLYMOUTH MEETING, Pa., July 25, 2023 /PRNewswire/ -- Harmony Biosciences selected the latest round of nonprofit organizations for its Patients at the Heart and Progress at the Heart awards, which provide funding toward interdisciplinary community initiatives that address complex challenges facing people living with sleep disorders and rare neurological diseases.
Jul 20, 2023 08:05 am ET
HARMONY BIOSCIENCES ANNOUNCES PLANS TO INITIATE PHASE 3 REGISTRATIONAL STUDY OF PITOLISANT IN PRADER-WILLI SYNDROME FOLLOWING POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION
PLYMOUTH MEETING, Pa., July 20, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, has successfully completed an End-of-Phase 2 meeting with FDA regarding its clinical development plan evaluating pitolisant as a potential treatment for excessive daytime sleepiness (EDS) in patients ages six and older with Prader-Willi syndrome (PWS). Harmony plans to initiate a Phase 3 registrational study in the fourth quarter of 2023. 
Jul 18, 2023 08:05 am ET
HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS ON AUGUST 1, 2023
PLYMOUTH MEETING, Pa., July 18, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report second quarter 2023 financial results on Tuesday, August 1, 2023, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on August 1, 2023, at 8:30 a.m. ET to discuss the results.
Jun 19, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Techtronic, Boxed, Coinbase, and Harmony and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Techtronic Industries Company Limited (OTC Pink: TTNDY), Boxed, Inc. (NYSE: BOXD), Coinbase Global, Inc. (NASDAQ: COIN), and...
Jun 06, 2023 08:05 am ET
HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023
PLYMOUTH MEETING, Pa., June 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the presentation of safety and efficacy data from a Phase 2 proof-of-concept study evaluating pitolisant for the treatment of excessive daytime sleepiness (EDS) in people with Prader-Willi syndrome (PWS) at the 37th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2023." The positive signal su
May 30, 2023 08:05 am ET
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 44th ANNUAL GLOBAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa., May 30, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on Tuesday, June 13, 2023, at 2:00 p.m. PT/ 5:00 p.m. ET.
May 25, 2023 08:05 am ET
HARMONY BIOSCIENCES COMPLETES ENROLLMENT OF PHASE 3 REGISTRATIONAL INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA
PLYMOUTH MEETING, Pa., May 25, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that its Phase 3 registrational INTUNE study evaluating the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia (IH) has completed enrollment nine months before its estimated enrollment completion date. Topline results are anticipated the fourth quarter of 2023.
May 12, 2023 07:00 pm ET
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harmony Biosciences Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences" or "the Company") (NASDAQ:HRMY) for violations of the securities laws.
May 10, 2023 08:05 am ET
HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETING
Late-breaking Phase 2 proof-of-concept study in Prader-Willi syndrome accepted for poster presentation
May 02, 2023 07:30 am ET
Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results...
Apr 24, 2023 08:05 am ET
HARMONY BIOSCIENCES ANNOUNCES JEFFREY M. DAYNO, M.D. APPOINTED PRESIDENT & CHIEF EXECUTIVE OFFICER
PLYMOUTH MEETING, Pa., April 24, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Jeffrey M. Dayno, M.D., has been appointed President and Chief Executive Officer by the Company's Board of Directors and has been elected to join as a member of the Board.
Apr 23, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating LivePerson, and Harmony and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against LivePerson, Inc. (NASDAQ: LPSN), and Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY). Our investigations concern whether...
Apr 20, 2023 10:04 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Harmony Biosciences (HRMY) Investors with Substantial Losses to Contact Firm, Firm Investigating Possible Securities Law Violations
Hagens Berman urges Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/HRMY Contact An Attorney Now: [email protected]          844-916-0895...
Apr 20, 2023 08:05 am ET
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS ON MAY 2, 2023
PLYMOUTH MEETING, Pa., April 20, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report first quarter 2023 financial results on Tuesday, May 2, 2023, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on May 2, 2023, at 8:30 a.m. ET to discuss the results.
Apr 12, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating LivePerson, and Harmony and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against LivePerson, Inc. (NASDAQ: LPSN), and Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY). Our investigations concern whether...
Apr 11, 2023 01:36 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Harmony Biosciences (HRMY) Investors with Substantial Losses to Contact Firm, Firm Investigating Possible Securities Law Violations
Hagens Berman urges Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/HRMY Contact An Attorney Now: [email protected]...
Apr 09, 2023 02:08 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQ: HRMY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Apr 03, 2023 10:49 am ET
HRMY INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Harmony Biosciences (HRMY) Investors with Substantial Losses to Contact Firm, Firm Investigating Possible Securities Law Violati
Hagens Berman urges Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/HRMY Contact An Attorney Now: [email protected] 844-916-0895 Harmony...
Apr 02, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Nutanix and Harmony and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Nutanix, Inc. (NASDAQ: NTNX) and Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY). Our investigations concern whether these...
Mar 30, 2023 05:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQ:
Mar 30, 2023 03:06 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQ: HRMY) investors concerning the Company’s possible violations of federal securities laws.
Mar 29, 2023 09:00 pm ET
HARMONY ALERT: Bragar Eagel & Squire, P.C. is Investigating Harmony Biosciences Holdings, Inc. on Behalf of Harmony Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQ: HRMY) on behalf of Harmony stockholders. Our investigation concerns whether Harmony has violated the federal securities laws and/or engaged in other unlawful business practices.
Mar 29, 2023 08:55 pm ET
Harmony Biosciences Holdings: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Harmony Biosciences Holdings, Inc. (“Harmony Biosciences” or the “Company”) (NASDAQ: HRMY) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of...
Mar 29, 2023 06:00 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Harmony Biosciences Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences" or "the Company") (NASDAQ:HRMY) for violations of the securities laws.
Mar 29, 2023 03:51 pm ET
Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) Investors
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) (“Harmony Biosciences”)....
Mar 29, 2023 09:18 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harmony Biosciences Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. (“Harmony Biosciences” or “the Company”) (NASDAQ:
Mar 29, 2023 08:05 am ET
HARMONY BIOSCIENCES ANNOUNCES ACCELERATED TIMELINE FOR PHASE 3 INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA
PLYMOUTH MEETING, Pa., March 29, 2023 /PRNewswire/ --  Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced an accelerated timeline for completing its Phase 3 INTUNE study evaluating the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia (IH). The Company now expects to complete enrollment in the second quarter of 2023 with topline data anticipated in the fourth quarter of 2023.
Mar 28, 2023 07:58 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQ:
Mar 28, 2023 07:30 pm ET
Harmony Biosciences Holdings Shareholder News: Johnson Fistel Urges Investors with Losses to Reach Out Regarding Class Action Investigation - HRMY
Shareholder rights law firm Johnson Fistel, LLP is investigating whether Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose material,...
Mar 28, 2023 04:22 pm ET
Lost Money in Harmony Biosciences Holdings Inc.?
Shares of Harmony Biosciences plummeted 27% on Tuesday, March 28, 2023, after Scorpion Capital published a report alleging that serious health risks, including sudden death, occurred during foreign drug trials of Harmony Bioscience’s drug, Wakix. The report further alleges that the company concealed information from the FDA that would have prevented Wakix’s 2019 approval. Gibbs Law Group is looking into a potential Harmony Biosciences Class Action Lawsuit on behalf of investors who lost money in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY).
Mar 28, 2023 03:44 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Harmony Biosciences (HRMY) Investors with Substantial Losses to Contact Firm, Firm Investigating Possible Securities Law Violations
Hagens Berman urges Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/HRMY Contact An Attorney Now: [email protected]...
Mar 28, 2023 02:15 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harmony Biosciences Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. (“Harmony Biosciences” or “the Company”) (NASDAQ:
Mar 28, 2023 01:32 pm ET
EQUITY ALERT: Rosen Law Firm Encourages Harmony Biosciences Holdings, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – HRMY
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) resulting from allegations that Harmony Biosciences may have issued materially misleading business information to the investing public.
Mar 28, 2023 11:40 am ET
Investigation of Harmony Biosciences Holdings, Inc. (HRMY) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether Harmony Biosciences Holdings, Inc. (“Harmony Biosciences” or the “Company”) (NASDAQ: HRMY) complied with federal securities laws. On March 28, 2023, Scorpion Capital published a report alleging that...
Mar 28, 2023 11:25 am ET
Harmony Biosciences Investigated For Potential Securities Law Violations by Block & Leviton LLP; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Block & Leviton is investigating Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) for potential securities law violations. Investors who have lost money in their Harmony Biosciences investment should contact the firm to learn more about how they...
Feb 21, 2023 07:30 am ET
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results...
Feb 17, 2023 07:05 am ET
HARMONY BIOSCIENCES CERTIFIED AS A GREAT PLACE TO WORK® FOR FIFTH CONSECUTIVE YEAR
Recognition reinforces strong company culture and employee experience
Feb 07, 2023 07:05 am ET
HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ON FEBRUARY 21, 2023
PLYMOUTH MEETING, Pa., Feb. 7, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on February 21, 2023, at 8:30 a.m. ET to discuss the results.
Jan 06, 2023 03:39 pm ET
HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN
PLYMOUTH MEETING, Pa., Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity. The Harmony Board of Directors has named Jeffrey M. Dayno, MD, Harmony's Executive Vice President and Chief Medical Officer, as interim CEO effective immediately. Jef
Dec 22, 2022 07:05 am ET
HARMONY BIOSCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa., Dec. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that President and CEO, John C. Jacobs will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 4:30 p.m. PT/ 7:30 p.m. ET.
Nov 09, 2022 07:05 am ET
HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 34th ANNUAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa., Nov. 9, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference.
Nov 01, 2022 07:30 am ET
Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results...
Nov 01, 2022 07:20 am ET
HARMONY BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH PRADER-WILLI SYNDROME
PLYMOUTH MEETING, Pa., Nov. 1, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced initial topline results from its Phase 2 proof-of-concept study in patients with Prader-Willi syndrome (PWS), which showed a positive signal on improvement in the primary outcome related to excessive daytime sleepiness (EDS).
Oct 18, 2022 08:05 am ET
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS ON NOVEMBER 1, 2022
PLYMOUTH MEETING, Pa., Oct. 18, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report third quarter 2022 financial results on Tuesday, November 1, 2022, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on November 1, 2022, at 8:30 a.m. ET to discuss the results.
Sep 22, 2022 08:05 am ET
HARMONY BIOSCIENCES ANNOUNCES 2022 FUNDING RECIPIENTS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD PROGRAMS
PLYMOUTH MEETING, Pa., Sept. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced on the fourth annual World Narcolepsy Day, the funding recipients of its Patients at the Heart and Progress at the Heart award programs.
Aug 17, 2022 08:05 am ET
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
PLYMOUTH MEETING, Pa., Aug. 17, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company focused on delivering innovative therapies that improve the health of people living with rare neurological diseases, today announced that Harmony's management will participate in the following upcoming investor conferences:
Aug 02, 2022 07:30 am ET
Harmony Biosciences Reports Second Quarter 2022 Financial Results and Business Updates
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company focused on delivering innovative therapies that improve the health of people living with rare neurological diseases, today reported financial...
Jul 19, 2022 08:05 am ET
HARMONY BIOSCIENCES ANNOUNCES DATE OF SECOND QUARTER 2022 FINANCIAL RESULTS
PLYMOUTH MEETING, Pa., July 19, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's second quarter 2022 financial results on Tuesday, August 2, 2022. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.
Jun 06, 2022 08:05 am ET
HARMONY BIOSCIENCES PRESENTS POST-HOC ANALYSIS OF WAKIX® (PITOLISANT) PIVOTAL DATA IN ADULTS WITH HIGH BURDEN OF NARCOLEPSY SYMPTOMS
PLYMOUTH MEETING, Pa., June 6, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced results of a post-hoc analysis from the pivotal data evaluating the clinical impact of WAKIX® (pitolisant) on the reduction of excessive daytime sleepiness (EDS) and cataplexy in adults with a high burden of narcolepsy symptoms. The analysis was presented as a poster at the 36th Annual Meeting of the Associated Professional Sleep
May 05, 2022 09:15 am ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Harmony Biosciences Holdings, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, May 5, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY).
May 03, 2022 07:30 am ET
Harmony Biosciences Reports First Quarter 2022 Financial Results and Business Updates
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company focused on delivering innovative therapies that improve the health of people living with rare neurological diseases, today reported financial...
Apr 27, 2022 08:05 am ET
HARMONY BIOSCIENCES INITIATES PHASE 3 TRIAL OF PITOLISANT IN ADULT PATIENTS WITH IDIOPATHIC HYPERSOMNIA
PLYMOUTH MEETING, Pa., April 27, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the initiation of its Phase 3 trial evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia (IH), known as the INTUNE study. 
Apr 19, 2022 08:05 am ET
HARMONY BIOSCIENCES ANNOUNCES DATE OF FIRST QUARTER 2022 FINANCIAL RESULTS
PLYMOUTH MEETING, Pa., April 19, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's first quarter 2022 financial results on Tuesday, May 3, 2022. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.
Apr 07, 2022 08:05 am ET
HARMONY BIOSCIENCES OPENS APPLICATIONS FOR 2022 PROGRESS AT THE HEART PROGRAM
Program will award funding to select applications from non-profit organizations addressing disparities in rare neurological disease and sleep disorder communities
Apr 04, 2022 08:05 am ET
HARMONY BIOSCIENCES TO PARTICIPATE IN 21st ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa., April 4, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's President and CEO, John C. Jacobs, will present a company update and host investor meetings at the upcoming 21st Annual Needham Virtual Healthcare Conference.
Mar 31, 2022 08:05 am ET
HARMONY BIOSCIENCES CERTIFIED AS A GREAT PLACE TO WORK® FOR FOURTH CONSECUTIVE YEAR
PLYMOUTH MEETING, Pa., March 31, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the company was certified as a Great Place to Work® for the fourth consecutive year. This accolade is based on survey feedback from Harmony employees that evaluates workplace culture and the employee experience.
Mar 17, 2022 08:05 am ET
HARMONY BIOSCIENCES ANNOUNCES APPLICATIONS OPEN MARCH 18 FOR 2022 PATIENTS AT THE HEART PROGRAM
Funding supports the comprehensive needs of people affected by rare neurological diseases
Mar 09, 2022 07:05 am ET
HARMONY BIOSCIENCES TO PARTICIPATE IN TWO INVESTOR CONFERENCES IN MARCH
PLYMOUTH MEETING, Pa., March 9, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that its executive leaders will participate in the following upcoming virtual conferences:
Feb 28, 2022 07:30 am ET
Harmony Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results...
Feb 14, 2022 07:05 am ET
Harmony Biosciences Announces Date of Fourth Quarter and Full Year 2021 Financial Results
PLYMOUTH MEETING, Pa., Feb. 14, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's fourth quarter and full year 2021 financial results on Monday, February 28, 2022. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.
Jan 05, 2022 07:05 am ET
Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference
PLYMOUTH MEETING, Pa., Jan. 5, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's President and CEO, John C. Jacobs will present a company update and host investor meetings at the upcoming 40th Annual J.P. Morgan Healthcare Conference.
Dec 17, 2021 07:05 am ET
Harmony Biosciences to be Added to the Nasdaq Biotech Index
PLYMOUTH MEETING, Pa., Dec. 17, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NBI). Harmony's addition to the NBI will become effective prior to market open on Monday, December 20, 2021.
Dec 13, 2021 07:05 am ET
Harmony Biosciences Publishes Pitolisant Efficacy Data In CNS Drugs
PLYMOUTH MEETING, Pa., Dec. 13, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced publication of a data analysis in the December issue of CNS Drugs that evaluates time to onset of response to pitolisant for excessive daytime sleepiness (EDS) and cataplexy in adult patients with narcolepsy.
Dec 01, 2021 07:05 am ET
Harmony Biosciences Announces Plans To Initiate Phase 3 Clinical Trial For Treatment Of Idiopathic Hypersomnia
PLYMOUTH MEETING, Pa., Dec. 1, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for pitolisant for the treatment of idiopathic hypersomnia (IH). Harmony is planning to initiate a Phase 3 clinical trial to evaluate the safety and efficacy of pitolisant in adult patients with IH in the first half of 2022
Nov 22, 2021 03:05 pm ET
Harmony Biosciences Appoints Linda Szyper To Its Board Of Directors
PLYMOUTH MEETING, Pa., Nov. 22, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Linda Szyper to the Company's Board of Directors.
Nov 11, 2021 07:05 am ET
Harmony Biosciences To Participate In Two Investor Conferences In November
PLYMOUTH MEETING, Pa., Nov. 11, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's President and CEO, John C. Jacobs, will participate in fireside chats and host investor meetings at the following upcoming virtual conferences:
Nov 09, 2021 07:30 am ET
Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business Updates
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results...
Oct 26, 2021 08:05 am ET
Harmony Biosciences Announces Date of Third Quarter 2021 Financial Results
PLYMOUTH MEETING, Pa., Oct. 26, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's third quarter 2021 financial results on Tuesday, November 9, 2021. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.
Oct 21, 2021 08:05 am ET
Harmony Biosciences to be Added to the S&P SmallCap 600® Index
PLYMOUTH MEETING, Pa., Oct. 21, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will be added to the S&P SmallCap 600® Index, effective prior to the open of trading on Friday, October 22, 2021.
Oct 18, 2021 07:28 pm ET
Kite Realty Group Trust Set to Join S&P MidCap 400; Harmony Biosciences Holdings & LendingTree to Join S&P SmallCap 600
NEW YORK, Oct. 18, 2021 /PRNewswire/ -- S&P SmallCap 600 constituent Kite Realty Group Trust (NYSE:KRG) will replace LendingTree Inc. (NASD:TREE) in the S&P MidCap 400, LendingTree will replace Kite Realty Group Trust in the S&P SmallCap 600, and Harmony Biosciences Holdings Inc. (NASD:HRMY) will replace Retail Properties of America Inc. (NYSE:RPAI) in the S&P SmallCap 600 effective prior to the open of trading on Friday, October 22. Kite Realty Group Trust is acquiring Retail Properties of America in a deal expected to close soon pending final closing conditions. LendingTree
Sep 22, 2021 08:05 am ET
Harmony Biosciences Announces Winners of Patients at the Heart and Progress at the Heart on Third Annual World Narcolepsy Day
PLYMOUTH MEETING, Pa., Sept. 22, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced winners of the Patient at the Heart and Progress at the Heart programs in honor of the third annual World Narcolepsy Day.
Sep 02, 2021 08:05 am ET
Harmony Biosciences To Participate In Three Investor Conferences In September
PLYMOUTH MEETING, Pa., Sept. 2, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's President and CEO, John C. Jacobs, will participate in fireside chats and host investor meetings at the following upcoming virtual conferences: 
Aug 10, 2021 08:00 am ET
Harmony Biosciences Reports Second Quarter 2021 Financial Results and Business Updates
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results...
Aug 10, 2021 07:30 am ET
Harmony Biosciences And Blackstone Enter Into Strategic Financing Collaboration
PLYMOUTH MEETING, Pa. and NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, and Blackstone (NYSE: BX) today announced that they have entered into a strategic financing collaboration where funds managed by Blackstone have agreed to provide Harmony with up to $330 million of financing and growth capital.
Aug 09, 2021 08:05 am ET
Harmony Biosciences Acquires Asset With Novel Mechanism Of Action For The Potential Treatment Of Narcolepsy And Other Rare Neurological Diseases
PLYMOUTH MEETING, Pa., Aug. 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological diseases, today announced the acquisition of HBS-102 (formerly CSTI-100), a potential first-in-class molecule with a novel mechanism of action, from ConSynance Therapeutics, Inc., a clinical stage biotechnology company focused on rare central nervous system diseases. Under the terms of the agreement, Harmony will acquire full development and commer
Jul 29, 2021 08:05 am ET
John C. Jacobs, President And CEO Of Harmony Biosciences, Named An Ernst & Young (EY) Entrepreneur Of The Year 2021 Greater Philadelphia Award Winner
PLYMOUTH MEEETING, Pa., July 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that John C. Jacobs, President and CEO, has been named an EY Entrepreneur Of The Year® 2021 Greater Philadelphia Award Winner.
Jul 27, 2021 07:30 am ET
Harmony Biosciences Announces Date Of Second Quarter 2021 Financial Results
PLYMOUTH MEETING, Pa., July 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that it will issue a press release on the Company's second quarter 2021 financial results on Tuesday, August 10, 2021 at 8:00 a.m. ET. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.
Jun 29, 2021 08:05 am ET
Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy
PLYMOUTH MEETING, Pa., June 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced initiation of a Phase 2 clinical trial to evaluate the safety and efficacy of pitolisant for excessive daytime sleepiness (EDS) and other non-muscular symptoms in adult patients with type 1 myotonic dystrophy (DM1).
Jun 10, 2021 11:44 am ET
/C O R R E C T I O N -- Harmony Biosciences/
In the news release, Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting, issued June 10, 2021 by Harmony Biosciences over PR Newswire, we are advised by the company that the release has been updated. The complete, corrected release follows:
Jun 10, 2021 08:05 am ET
Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting
PLYMOUTH MEETING, Pa., June 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced results of a new analysis evaluating number needed to treat (NNT) and effect sizes for treatment with WAKIX® (pitolisant) that demonstrates the magnitude of its clinical effectiveness for excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The poster was presented at t
Jun 09, 2021 08:05 am ET
Harmony Biosciences Announces Applications for 2021 Patients At The Heart Grant Program Open June 9
PLYMOUTH MEETING, Pa., June 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced applications for its Patients at the Heart Grant Program open Wednesday, June 9, 2021 for patient-centric organizations working to support and address the challenges of people living with sleep disorders and rare diseases who experience excessive daytime sleepiness (EDS).
May 11, 2021 08:00 am ET
Harmony Biosciences Reports First Quarter 2021 Results and Business Updates
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical...
Mar 25, 2021 08:00 am ET
Harmony Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Business Updates
Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today...
Dec 17, 2020 07:05 am ET
Harmony Biosciences To Be Added To Russell 2000® And Russell 3000® Indexes
PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 17, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the Company will be added to the Russell 2000® and Russell 3000® Indexes effective after the U.S. market closes on Friday, December 18.
Dec 15, 2020 07:05 am ET
Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi Syndrome
PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 15, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the first patient has been enrolled in a Phase 2 trial evaluating the safety and efficacy of pitolisant for the treatment of excessive daytime sleepiness (EDS) and other key symptoms in patients with Prader-Willi Syndrome (PWS).
Nov 12, 2020 08:00 am ET
Harmony Biosciences Reports Third Quarter 2020 Financial Results and Business Updates
Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today...
Nov 11, 2020 04:00 pm ET
Harmony Biosciences Appoints Mark Graf And Eric Motley To Its Board Of Directors
PLYMOUTH MEETING, Pa. and CHICAGO, Nov. 11, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the appointment of Mark Graf and Eric Motley to the Company's Board of Directors. Mark Graf is an executive with deep financial expertise as well as an experienced board member with a strong background in corporate governance. Eric Motley is an expert in human capital development
Oct 28, 2020 08:05 am ET
Harmony Biosciences Announces Date Of Third Quarter 2020 Financial Results
PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 28, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that it will issue a press release on the Company's third quarter financial results on Thursday, November 12, 2020 at 8:00 a.m. ET. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.
Oct 14, 2020 08:05 am ET
Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy
PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 14, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has approved WAKIX® (pitolisant) for the treatment of cataplexy in adult patients with narcolepsy. WAKIX is the first and only treatment approved by the FDA for people with excessive daytime sleepiness or cataplexy associated with narcol

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.